Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of VE202 in mild-to-moderate ulcerative colitis
NL-OMON59253Phase 2Completed
- Sponsor
- Vedanta Biosciences
- Start
- Oct 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VE202 in autoimmune colitis (3 arms), sponsored by Vedanta Biosciences. Primary endpoints: Endoscopic response rate at Day 56, Grade 3 or higher treatment-emergent adverse events related to study treatment and 2 more. Started Oct 2023; status: completed.
02
Drugs
VE202
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59253.